Corcept Therapeutics CORT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $99.65M-29.4% | $141.21M+33.0% | $106.14M+4.7% | $101.42M-9.9% | ||
| $1.15M+44.5% | $795K-23.7% | $1.04M-17.2% | $1.26M-58.4% | ||
| $84.5M+37.7% | $61.35M+25.4% | $48.94M+15.3% | $42.44M-1.1% | ||
| $142M-28.4% | $198.3M+56.5% | $126.68M+5.3% | $120.32M-28.3% | ||
| $211K-90.3% | $2.17M+1,463% | $139K-66.3% | $413K-11.9% | ||
| —— | -$177.6M— | —— | -$114.33M-184% | ||
| $172.92M+1,004% | $15.66M— | $0— | $0— | ||
| -$220.37M-677% | -$28.35M+81.0% | -$149.49M-765% | -$17.28M+94.3% | ||
| —— | -$7.89M— | —— | —— | ||
| $141.79M-27.7% | $196.12M+55.0% | $126.54M+5.5% | $119.91M-28.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corcept Therapeutics generate?
- Corcept Therapeutics (CORT) generated $120.5M in operating cash flow over the trailing twelve months.
- What is Corcept Therapeutics's free cash flow?
- After $308.0K of capital expenditures, Corcept Therapeutics's free cash flow was $120.1M over the trailing twelve months, down 32.1% year over year.
- Where does Corcept Therapeutics's cash flow data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
